On this page

hydrocortisone

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
hydrocortisone
Generic name
hydrocortisone
Dosage form
Lotion
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
5
NDC product codes
10
Packages
13
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone 1 g/100g 604449 View
Hydrocortisone 1.14 g/114g 604449 View
Hydrocortisone 10 mg/mL 604449 View
Hydrocortisone 20 mg/mL 604449 View
Hydrocortisone 25 mg/mL 604449 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Lotion
Route of administration
Topical
Presentations
23

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
089074
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 26, 1985
Sponsor
PADAGIS US
Products on application
1
Submissions recorded
13
Products approved under application 089074.
Product Trade name Form Strength Ingredient Status TE Flags
089074-001 STIE-CORT LOTION HYDROCORTISONE Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 089074.
Type No. Action Status Date Review
Supplement 15 Labeling Approved November 28, 2007 —
Supplement 14 Manufacturing (CMC) Approved August 16, 2001 —
Supplement 13 Manufacturing (CMC) Approved August 3, 1998 —
Supplement 10 Manufacturing (CMC) Approved January 17, 1996 —
Supplement 9 Labeling Approved January 17, 1996 —
Supplement 12 Manufacturing (CMC) Approved September 14, 1995 —
Supplement 8 Labeling Approved September 14, 1995 —
Supplement 7 Manufacturing (CMC) Approved September 14, 1995 —
Supplement 11 Manufacturing (CMC) Approved April 14, 1995 —
Supplement 2 Manufacturing (CMC) Approved May 14, 1986 —
Supplement 1 Manufacturing (CMC) Approved May 14, 1986 —
Supplement 4 Manufacturing (CMC) Approved April 11, 1986 —
Original application 1 Approved November 26, 1985 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260825). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN OTC DRUG · 20260825 HUMAN OTC DRUG · 20260722 HUMAN PRESCRIPTION DRUG · 20260708 HUMAN OTC DRUG · 20260317

Indications and Usage

openFDA Drug Labeling

Uses For the temporary relief associated with minor skin irritations, inflammation and rashes due to: eczema seborrheic dermatitis psoriasis insect bites poison ivy, oak, sumac soaps detergents cosmetics jewelry external genital and anal itching. Other uses of this product should be only under the advice and supervision of a doctor.

Purpose Antipruritic (Anti-itch)

Dosage and Administration

openFDA Drug Labeling

Directions Adults and children 2 years of age and older: apply to affected area not more than 3 to 4 times daily Children under 2 years of age: do not use, consult a doctor For External Anal Itching Users adults: when practical, cleanse the affected area with mild soap and warm water and rinse thoroughly, and gently dry by patting or blotting with toilet tissue or a soft cloth before application of this product children under 12 years of age: consult a doctor

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Warnings and Cautions

openFDA Drug Labeling

Rx Only For external use only Not for opthalmic use

Warnings For external use only avoid contact with the eyes Stop using this product and ask a doctor if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days before you begin using any other hydrocortisone product Do not use this product and ask a doctor if you have a vaginal discharge before treating diaper rash before using on children under 2 years of age For external anal itching users do not exceed the recommended daily dosage unless directed by a doctor in case of bleeding, consult a doctor promptly do not put this product into the rectum by using fingers or any mechanical device or applicator Keep this and all drugs out of the reach of children

Do not use this product and ask a doctor if you have a vaginal discharge before treating diaper rash before using on children under 2 years of age

Ask a Doctor

openFDA Drug Labeling

Stop use and ask a doctor if • condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor

Stop use and ask a doctor if Condition worsens If symptoms persist for more than 7 days or clear up and occur again within a few days. Discontinue use of this product and do not begin use of any other hydrocortisone product unless you have consulted a doctor. Do no use for diaper rash. Consult a doctor.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an aproximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermitis, allergic contact dermatis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Allegis Holdings, LLC at 1-866-633-9033 or FDA at 1-800-FDA-1088 or https://fda.gov/Safety/MedWatch/

Description

openFDA Drug Labeling

DESCRIPTION Each mL of Hydrocortisone Lotion USP, 2.5% contains 25 mg of hydrocortisone, USP in a vehicle consisting of carbomer homopolymer type C, ceteareth-20, cetyl alcohol, dehydroacetic acid, DMDM hydantoin, fragrance, glyceryl stearate, isopropyl palmitate, lactic acid, light mineral oil, myristyl alcohol, myristyl lactate, PEG-100 stearate, purified water, sodium hydroxide, sodium PCA, and stearyl alcohol. Chemically, hydrocortisone is [Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11ß)-] with the molecular formula C 21 H 30 O 5 and is represented by the following structural formula: Its molecular weight is 362.46 and its CAS Registry Number is 50-23-7. The topical corticosteroids, including hydrocortisone, constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. chemical structure.png

Active Ingredient

openFDA Drug Labeling

Active Ingredient Hydrocortisone 1% (Micronized)

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Hydrocortisone Lotion USP, 2.5% is available as follow: NDC: 72162-1441-4: 2 fl oz (59 mL) in a BOTTLE NDC: 72162-1441-7: 4 fl oz (118 mL) in a BOTTLE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Keep tightly closed. Keep out of the reach of children. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Adverse event reports

Source: openFDA FAERS
123,956
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
71399-0120-1 71399-0120 AKRON PHARMA INC 1 BOTTLE in 1 CARTON (71399-0120-1) / 120 mL in 1 BOTTLE September 13, 2024
71297-010-01 71297-010 Allegis Holdings LLC 1 BOTTLE, WITH APPLICATOR in 1 BOX (71297-010-01) / 29.6 mL in 1 BOTTLE, WITH APPLICATOR June 10, 2024
71297-010-02 71297-010 Allegis Holdings LLC 1 BOTTLE, WITH APPLICATOR in 1 BOX (71297-010-02) / 59.2 mL in 1 BOTTLE, WITH APPLICATOR June 10, 2024
72288-469-25 72288-469 Amazon.com Services LLC 1 TUBE in 1 CARTON (72288-469-25) / 99 g in 1 TUBE (72288-469-00) August 25, 2026
63629-2529-1 63629-2529 Bryant Ranch Prepack 118 mL in 1 BOTTLE (63629-2529-1) May 23, 2008
63629-8668-1 63629-8668 Bryant Ranch Prepack 59 mL in 1 BOTTLE (63629-8668-1) September 24, 2008
63629-9416-1 63629-9416 Bryant Ranch Prepack 118 mL in 1 BOTTLE (63629-9416-1) August 23, 2022
71335-2918-1 71335-2918 Bryant Ranch Prepack 118 mL in 1 BOTTLE (71335-2918-1) October 28, 2025
72162-1441-4 72162-1441 Bryant Ranch Prepack 59 mL in 1 BOTTLE (72162-1441-4) February 8, 2024
72162-1441-7 72162-1441 Bryant Ranch Prepack 118 mL in 1 BOTTLE (72162-1441-7) February 8, 2024
0394-0859-32 0394-0859 Mericon Industries 12 BOTTLE, DISPENSING in 1 BOX (0394-0859-32) / 114 g in 1 BOTTLE, DISPENSING June 12, 2023
45802-937-16 45802-937 Padagis Israel Pharmaceuticals Ltd 59 mL in 1 BOTTLE (45802-937-16) September 24, 2008
45802-937-26 45802-937 Padagis Israel Pharmaceuticals Ltd 118 mL in 1 BOTTLE (45802-937-26) May 23, 2008
71399-0120 71399-0120 AKRON PHARMA INC — September 13, 2024
71297-010 71297-010 Allegis Holdings LLC — June 10, 2024
72288-469 72288-469 Amazon.com Services LLC — August 25, 2026
63629-2529 63629-2529 Bryant Ranch Prepack — May 23, 2008
63629-8668 63629-8668 Bryant Ranch Prepack — May 23, 2008
63629-9416 63629-9416 Bryant Ranch Prepack — May 23, 2008
71335-2918 71335-2918 Bryant Ranch Prepack — May 23, 2008
72162-1441 72162-1441 Bryant Ranch Prepack — May 23, 2008
0394-0859 0394-0859 Mericon Industries — June 12, 2023
45802-937 45802-937 Padagis Israel Pharmaceuticals Ltd — May 23, 2008

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.